

INFORME DE BÚSQUEDA DE PATENTES

N° de solicitud: NC2017/0005203

CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)

PALABRAS CLAVE UTILIZADAS ((AB=(oxymorphone NEAR/200 diflunisal)) OR (TI=(oxymorphone NEAR/200 diflunisal)) OR (CL=(oxymorphone NEAR/200 diflunisal))) (conjugate)

CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA
CIP: A61K47/48; C07D221/28
CPC: A61K31/485; A61K47/48038; A61K47/48061; A61K47/481; A61K47/542; A61K47/545; A61K47/55; C07D221/28; C07D489/08

DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)

Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI (Obligatoria)	----	----	----	----
USPTO	US2013150395	13/06/2013	----	A
	US4668685	26/05/1987	----	A
Patbase*	EP0046270	24/02/1982	----	A
	WO2011/002995	06/01/2011	----	A
EPOQUE NET*	WO2010/106082	23/09/2010	----	A
	WO2009/138437	19/11/2009	---	A
	WO2002/098427	12/12/2002	----	A
Google Patents	WO2010/107457	23/09/2010	----	A
	WO2012/008984	19/01/2012	----	A
	WO2011/002991	06/01/2011	----	A
Espacenet	US2008318905	25/12/2008	1 - 6, 8 - 10	Y
	WO2013/063204	02/05/2013	1 - 11	Y
	WO2011/009015	20/01/2011	----	A
	WO2007/140272	06/12/2007	----	A

*** Categorías especiales de documentos citados:

“A” documento que define el estado general de la técnica no considerado como particularmente relevante.
 “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior.
 “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.
 “X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado.
 “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.

**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.

Literatura no patente

**Se incluye entre otros, toda la referencia de la literatura no patente.

Szabolcs Béni, Gergo Tóth, Béla Noszál, Sándor Hosztafi. Preparation of benzoate esters of morphine and its derivatives. Monatsh Chem, 2012, 143, 1431-1440. Fig. 1 - 4.

Fecha del reporte de búsqueda:

6/septiembre/2018

BUSCAR SOLICITUDES



Criterio de búsqueda						
7 Casos asociados						
Número de solicitud	Tipo de solicitud	Título/Denominación	Etiqueta	Fecha de radicación	Estado(s)	Examinador Principal Titular
☐ 12000250	Patente PCT	COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UN CONJUGADO DE BENZOATO DE HIDROCODONA Y EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES		02 ene 2012	Concedido	CLARA INES BARRERA GARZON KEMPHARM INC.
☐ 13282303	Patente PCT	COMPOSICIONES DE PROFÁRMACO QUE COMPRENDE POR LO MENOS UN CONJUGADO DE METILFENIDATO Y UN AMINOÁCIDO ESTÁNDAR, AMINOÁCIDOS NO ESTÁNDAR O AMINOÁCIDOS SINTÉTICOS UNIDOS MEDIANTE UN ENLACE AMIDA		02 dic 2013	Negada	SIC KEMPHARM INC.
☐ 14089601	Patente PCT	CONJUGADOS DE HIDROMORFONA CON ÁCIDO BENZOICO, DERIVADOS DE ÁCIDO BENZOICO Y ÁCIDO HETEROARILCARBOXÍLICO, PROFÁRMACOS, MÉTODOS DE PREPARACIÓN Y USO DE LOS MISMOS		28 abr 2014	Negada	SIC KEMPHARM INC.
☐ NC2017/0065201	Patente PCT	ÁCIDO BENZOÍCO, DERIVADOS DE ÁCIDO BENZOÍCO Y CONJUGADOS HETEROARILCARBOXÍLICO DE LA OXICODONA		25 may 2017	Bajo Examen de Fondo	LEONARDO FERNANDEZ RODRIGUEZ KEMPHARM INC.
☐ NC2017/0065203	Patente PCT	ACIDO BENZOICO, DERIVADOS DE ACIDO BENZOICO Y CONJUGADOS DE ACIDO CARBOXILICO DE HETEROARILLO DE OXIMORFONA, PROFARMACOS, METODOS DE FABRICACION Y USO DE LOS MISMOS		25 may 2017	Bajo Examen de Fondo	LEONARDO FERNANDEZ RODRIGUEZ KEMPHARM INC.

fiveIPoffices - CCD

Search Help

Number: WO/2016/089951 Search examples: BP1612402, US2006000447A1, JP20090214944

WO2015063351

Hide CCD viewer Double inspector Timeline

CCD Viewer Export

US2013150395.A1 (JP20170529821) [also published as]

Citations only view Compact view Sort by country Filter (2)

Classifications & fields searched

4 Biblio Description Claims Original document

Bibliographic data: US 2013150395 (A1)

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof

Publication date: 13 June 2013

Inventor(s): MICKLE TRAVIS [US]; GUENTHER SVEN [US]; CHI GUOCHEN [US]; KANSKI JAROSLAW [US]; MARTIN ANDREA K [US]; BERA BINDU [US]

Applicant(s): KEMPHARM INC [US]; KEMPHARM INC [US]

Classifications: International: C07D489/02

Cooperative: A61K31/185; A61K31/485; A61K31/616; A61K47/542; A61K47/55; A61K9/0019; A61K9/0043; A61K9/0053

Application number: US201213660112 20121025

Priority number(s): US201213660112 20121025

US201161551600P 20111026

US201261657201P 20120608

Abstract of US 2013150395 (A1)

The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-alpha-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.


Simple families: 1 Total family members: 13 (3)

#	Search query	Results	Options
2	STAC-(oxymorphone and difunisal and (conjugat* OR prodrug))	34	View Browse Hits Optimise more...
1	STAC-(oxymorphone and difunisal)	107	View Browse Hits Optimise more...

[Information](#) | [Shortcuts](#)

Command Reference

[Bibliographic data](#)
[Textual data](#)



STN[®] Projects Working On – NC2017/0005203

Welcome, Leonardo Fernandez Layout Settings STN Help Contact Us Sign Out

ChApus, REGISTRY

Enter your query...

17 FILTERS (7) Remove Filters Update Query

6. Patent 2002 Sustained-release analgesic compounds

Ashiton, Paul • Smith, Thomas J. • Cynkowska, Grazyna • Mcdunas, Edmund
Control Delivery Systems, United States (US)
PCT Int. Appl., pp. 54 In English
2002:946115 (DN 130:16594)

Abstract

A pharmaceutically active inventive compd. comprises two independently active analgesic moieties covalently conjoined through a physiol. labile linker. A preferred embodiment comprises an opioid, such as morphine, covalently linked to at least one analgesic compd. selected from the group consisting of an opioid or a non-opioid compd. through a physiol. labile linker. Suitable covalent linkers are covalently bonded to the two independently active analgesic compounds through one or more lactone, lactam, or sulfonamide linkages. Suitable linkers include endogenous carboxylate, amide, and sulfonamide moieties, and exogenous moieties that form the aforementioned lactone, lactam or sulfonamide linkages.

Supplementary Terms: sustained release pharmaceutical analgesic **conjugate**

Substance Indexing

22494-42-4OP, Diflunisol, **conjugates** with analgesics
76-41-5OP, Oxycodone, **conjugates** with analgesics
303-80-2OP, Acetaminophen, **conjugates** with analgesics
123-30-8OP, dextropropoxyphene, **conjugates** with analgesics
13307-86-5OP, Diclofenac, **conjugates** with analgesics
15687-27-2OP, Ibuprofen, **conjugates** with analgesics
20594-83-4OP, Halobutrine, **conjugates** with analgesics
21296-18-4OP, Oxycodone, **conjugates** with analgesics
22071-15-4OP, Ketorolac, **conjugates** with analgesics
22204-53-3OP, Naproxen, **conjugates** with analgesics
26171-23-3OP, Telenor, **conjugates** with analgesics
28423-46-5OP, **conjugates** with analgesics
29679-58-2OP, Fentanyl, **conjugates** with analgesics
359-82-2OP, Pentazocine, **conjugates** with analgesics
36322-60-4OP, Propocam, **conjugates** with analgesics
38194-50-2OP, Salindac, **conjugates** with analgesics
41340-25-4OP, Etodolac, **conjugates** with analgesics
42408-82-2OP, Butorphanol, **conjugates** with analgesics
42926-53-5OP, Nabumetone, **conjugates** with analgesics
466-59-4OP, Hydromorphone, **conjugates** with analgesics
50-02-2OP, Desamethasone, **conjugates** with analgesics
50-24-4OP, Prednisolone, **conjugates** with analgesics
50-76-2OP, Aspirin, **conjugates** with analgesics
5104-49-4OP, Flurbiprofen, **conjugates** with analgesics

Extended Patent Family

6. Sustained-release analgesic compounds

Inventor: Ashiton, Paul
Smith, Thomas J.
Cynkowska, Grazyna
Mcdunas, Edmund

Patent Assignee: Control Delivery Systems, United States (US)

Source: PCT Int. Appl., pp. 54 In English
CODEN: P5002

Document Type: Patent

Document ID: 2002:946115 (DN 130:16594)

Patent Information

Number	Kind	Date	Number	Application	Date	Number	Priority	Date
WO/2002098427	A2	20020212	WO/2002-051763		20020605	US/2001-26558P		20010605

[Show ChApus Patent Family](#)
[Show Patent Classification Overview](#)

Abstract

A pharmaceutically active inventive compd. comprises two independently active analgesic moieties covalently conjoined through a physiol. labile linker. A preferred embodiment comprises an opioid, such as morphine, covalently linked to at least one analgesic compd. selected from the group consisting of an opioid or a non-opioid compd. through a physiol. labile linker. Suitable covalent linkers are covalently bonded to the two independently active analgesic compounds through one or more lactone, lactam, or sulfonamide linkages. Suitable linkers include endogenous carboxylate, amide, and sulfonamide moieties, and exogenous moieties that form the aforementioned lactone, lactam or sulfonamide linkages.

Supplementary Terms: sustained release pharmaceutical analgesic **conjugate**

Classification Codes

CA Section Code: Pharmaceuticals (83)

Substance Indexing (73)

477779-35-4P
477779-37-4P
477779-39-4P

Selected: 0 | Total: 0

About STN Terms & Conditions Copyright © 2018 American Chemical Society. All Rights Reserved.

Structure Editor

Draw or change atoms or bonds. [Shortcut Keys](#)

Atom Short

Bond Type

- Chain
- Ring
- Ring / Chain

Bond Value

- Exact
- Normalized
- Exact / Normalized

Node Type

- Chain
- Ring
- Ring / Chain

Generic Definition

- Saturated / Unsaturated
- Linear / Branched
- Monocyclic / Polycyclic
- 1 hetero atom / 2+ hetero atoms
- 1-6 carbons / 7+ carbons

Match Level

- Atom
- Class
- Any

Element Count Level

- Limited
- Unlimited

Other Node Attributes

- Mass
- Valency
- Hydrogen Count
- Non-Hydrogen Count
- Element Count

OK **Cancel**

Chemical Structure:

O=C1C(=C(C=C1)C(=O)O2C(=C(C=C2)C(=O)O3C(=C(C=C3)C(=O)O4C(=C(C=C4)C(=O)O5C(=C(C=C5)C(=O)O6C(=C(C=C6)C(=O)O7C(=C(C=C7)C(=O)O8C(=C(C=C8)C(=O)O9C(=C(C=C9)C(=O)O10C(=C(C=C10)C(=O)O11C(=C(C=C11)C(=O)O12C(=C(C=C12)C(=O)O13C(=C(C=C13)C(=O)O14C(=C(C=C14)C(=O)O15C(=C(C=C15)C(=O)O16C(=C(C=C16)C(=O)O17C(=C(C=C17)C(=O)O18C(=C(C=C18)C(=O)O19C(=C(C=C19)C(=O)O20C(=C(C=C20)C(=O)O21C(=C(C=C21)C(=O)O22C(=C(C=C22)C(=O)O23C(=C(C=C23)C(=O)O24C(=C(C=C24)C(=O)O25C(=C(C=C25)C(=O)O26C(=C(C=C26)C(=O)O27C(=C(C=C27)C(=O)O28C(=C(C=C28)C(=O)O29C(=C(C=C29)C(=O)O30C(=C(C=C30)C(=O)O31C(=C(C=C31)C(=O)O32C(=C(C=C32)C(=O)O33C(=C(C=C33)C(=O)O34C(=C(C=C34)C(=O)O35C(=C(C=C35)C(=O)O36C(=C(C=C36)C(=O)O37C(=C(C=C37)C(=O)O38C(=C(C=C38)C(=O)O39C(=C(C=C39)C(=O)O40C(=C(C=C40)C(=O)O41C(=C(C=C41)C(=O)O42C(=C(C=C42)C(=O)O43C(=C(C=C43)C(=O)O44C(=C(C=C44)C(=O)O45C(=C(C=C45)C(=O)O46C(=C(C=C46)C(=O)O47C(=C(C=C47)C(=O)O48C(=C(C=C48)C(=O)O49C(=C(C=C49)C(=O)O50C(=C(C=C50)C(=O)O51C(=C(C=C51)C(=O)O52C(=C(C=C52)C(=O)O53C(=C(C=C53)C(=O)O54C(=C(C=C54)C(=O)O55C(=C(C=C55)C(=O)O56C(=C(C=C56)C(=O)O57C(=C(C=C57)C(=O)O58C(=C(C=C58)C(=O)O59C(=C(C=C59)C(=O)O60C(=C(C=C60)C(=O)O61C(=C(C=C61)C(=O)O62C(=C(C=C62)C(=O)O63C(=C(C=C63)C(=O)O64C(=C(C=C64)C(=O)O65C(=C(C=C65)C(=O)O66C(=C(C=C66)C(=O)O67C(=C(C=C67)C(=O)O68C(=C(C=C68)C(=O)O69C(=C(C=C69)C(=O)O70C(=C(C=C70)C(=O)O71C(=C(C=C71)C(=O)O72C(=C(C=C72)C(=O)O73C(=C(C=C73)C(=O)O74C(=C(C=C74)C(=O)O75C(=C(C=C75)C(=O)O76C(=C(C=C76)C(=O)O77C(=C(C=C77)C(=O)O78C(=C(C=C78)C(=O)O79C(=C(C=C79)C(=O)O80C(=C(C=C80)C(=O)O81C(=C(C=C81)C(=O)O82C(=C(C=C82)C(=O)O83C(=C(C=C83)C(=O)O84C(=C(C=C84)C(=O)O85C(=C(C=C85)C(=O)O86C(=C(C=C86)C(=O)O87C(=C(C=C87)C(=O)O88C(=C(C=C88)C(=O)O89C(=C(C=C89)C(=O)O90C(=C(C=C90)C(=O)O91C(=C(C=C91)C(=O)O92C(=C(C=C92)C(=O)O93C(=C(C=C93)C(=O)O94C(=C(C=C94)C(=O)O95C(=C(C=C95)C(=O)O96C(=C(C=C96)C(=O)O97C(=C(C=C97)C(=O)O98C(=C(C=C98)C(=O)O99C(=C(C=C99)C(=O)O100C(=C(C=C100)C(=O)O101C(=C(C=C101)C(=O)O102C(=C(C=C102)C(=O)O103C(=C(C=C103)C(=O)O104C(=C(C=C104)C(=O)O105C(=C(C=C105)C(=O)O106C(=C(C=C106)C(=O)O107C(=C(C=C107)C(=O)O108C(=C(C=C108)C(=O)O109C(=C(C=C109)C(=O)O110C(=C(C=C110)C(=O)O111C(=C(C=C111)C(=O)O112C(=C(C=C112)C(=O)O113C(=C(C=C113)C(=O)O114C(=C(C=C114)C(=O)O115C(=C(C=C115)C(=O)O116C(=C(C=C116)C(=O)O117C(=C(C=C117)C(=O)O118C(=C(C=C118)C(=O)O119C(=C(C=C119)C(=O)O120C(=C(C=C120)C(=O)O121C(=C(C=C121)C(=O)O122C(=C(C=C122)C(=O)O123C(=C(C=C123)C(=O)O124C(=C(C=C124)C(=O)O125C(=C(C=C125)C(=O)O126C(=C(C=C126)C(=O)O127C(=C(C=C127)C(=O)O128C(=C(C=C128)C(=O)O129C(=C(C=C129)C(=O)O130C(=C(C=C130)C(=O)O131C(=C(C=C131)C(=O)O132C(=C(C=C132)C(=O)O133C(=C(C=C133)C(=O)O134C(=C(C=C134)C(=O)O135C(=C(C=C135)C(=O)O136C(=C(C=C136)C(=O)O137C(=C(C=C137)C(=O)O138C(=C(C=C138)C(=O)O139C(=C(C=C139)C(=O)O140C(=C(C=C140)C(=O)O141C(=C(C=C141)C(=O)O142C(=C(C=C142)C(=O)O143C(=C(C=C143)C(=O)O144C(=C(C=C144)C(=O)O145C(=C(C=C145)C(=O)O146C(=C(C=C146)C(=O)O147C(=C(C=C147)C(=O)O148C(=C(C=C148)C(=O)O149C(=C(C=C149)C(=O)O150C(=C(C=C150)C(=O)O151C(=C(C=C151)C(=O)O152C(=C(C=C152)C(=O)O153C(=C(C=C153)C(=O)O154C(=C(C=C154)C(=O)O155C(=C(C=C155)C(=O)O156C(=C(C=C156)C(=O)O157C(=C(C=C157)C(=O)O158C(=C(C=C158)C(=O)O159C(=C(C=C159)C(=O)O160C(=C(C=C160)C(=O)O161C(=C(C=C161)C(=O)O162C(=C(C=C162)C(=O)O163C(=C(C=C163)C(=O)O164C(=C(C=C164)C(=O)O165C(=C(C=C165)C(=O)O166C(=C(C=C166)C(=O)O167C(=C(C=C167)C(=O)O168C(=C(C=C168)C(=O)O169C(=C(C=C169)C(=O)O170C(=C(C=C170)C(=O)O171C(=C(C=C171)C(=O)O172C(=C(C=C172)C(=O)O173C(=C(C=C173)C(=O)O174C(=C(C=C174)C(=O)O175C(=C(C=C175)C(=O)O176C(=C(C=C176)C(=O)O177C(=C(C=C177)C(=O)O178C(=C(C=C178)C(=O)O179C(=C(C=C179)C(=O)O180C(=C(C=C180)C(=O)O181C(=C(C=C181)C(=O)O182C(=C(C=C182)C(=O)O183C(=C(C=C183)C(=O)O184C(=C(C=C184)C(=O)O185C(=C(C=C185)C(=O)O186C(=C(C=C186)C(=O)O187C(=C(C=C187)C(=O)O188C(=C(C=C188)C(=O)O189C(=C(C=C189)C(=O)O190C(=C(C=C190)C(=O)O191C(=C(C=C191)C(=O)O192C(=C(C=C192)C(=O)O193C(=C(C=C193)C(=O)O194C(=C(C=C194)C(=O)O195C(=C(C=C195)C(=O)O196C(=C(C=C196)C(=O)O197C(=C(C=C197)C(=O)O198C(=C(C=C198)C(=O)O199C(=C(C=C199)C(=O)O200C(=C(C=C200)C(=O)O201C(=C(C=C201)C(=O)O202C(=C(C=C202)C(=O)O203C(=C(C=C203)C(=O)O204C(=C(C=C204)C(=O)O205C(=C(C=C205)C(=O)O206C(=C(C=C206)C(=O)O207C(=C(C=C207)C(=O)O208C(=C(C=C208)C(=O)O209C(=C(C=C209)C(=O)O210C(=C(C=C210)C(=O)O211C(=C(C=C211)C(=O)O212C(=C(C=C212)C(=O)O213C(=C(C=C213)C(=O)O214C(=C(C=C214)C(=O)O215C(=C(C=C215)C(=O)O216C(=C(C=C216)C(=O)O217C(=C(C=C217)C(=O)O218C(=C(C=C218)C(=O)O219C(=C(C=C219)C(=O)O220C(=C(C=C220)C(=O)O221C(=C(C=C221)C(=O)O222C(=C(C=C222)C(=O)O223C(=C(C=C223)C(=O)O224C(=C(C=C224)C(=O)O225C(=C(C=C225)C(=O)O226C(=C(C=C226)C(=O)O227C(=C(C=C227)C(=O)O228C(=C(C=C228)C(=O)O229C(=C(C=C229)C(=O)O230C(=C(C=C230)C(=O)O231C(=C(C=C231)C(=O)O232C(=C(C=C232)C(=O)O233C(=C(C=C233)C(=O)O234C(=C(C=C234)C(=O)O235C(=C(C=C235)C(=O)O236C(=C(C=C236)C(=O)O237C(=C(C=C237)C(=O)O238C(=C(C=C238)C(=O)O239C(=C(C=C239)C(=O)O240C(=C(C=C240)C(=O)O241C(=C(C=C241)C(=O)O242C(=C(C=C242)C(=O)O243C(=C(C=C243)C(=O)O244C(=C(C=C244)C(=O)O245C(=C(C=C245)C(=O)O246C(=C(C=C246)C(=O)O247C(=C(C=C247)C(=O)O248C(=C(C=C248)C(=O)O249C(=C(C=C249)C(=O)O250C(=C(C=C250)C(=O)O251C(=C(C=C251)C(=O)O252C(=C(C=C252)C(=O)O253C(=C(C=C253)C(=O)O254C(=C(C=C254)C(=O)O255C(=C(C=C255)C(=O)O256C(=C(C=C256)C(=O)O257C(=C(C=C257)C(=O)O258C(=C(C=C258)C(=O)O259C(=C(C=C259)C(=O)O260C(=C(C=C260)C(=O)O261C(=C(C=C261)C(=O)O262C(=C(C=C262)C(=O)O263C(=C(C=C263)C(=O)O264C(=C(C=C264)C(=O)O265C(=C(C=C265)C(=O)O266C(=C(C=C266)C(=O)O267C(=C(C=C267)C(=O)O268C(=C(C=C268)C(=O)O269C(=C(C=C269)C(=O)O270C(=C(C=C270)C(=O)O271C(=C(C=C271)C(=O)O272C(=C(C=C272)C(=O)O273C(=C(C=C273)C(=O)O274C(=C(C=C274)C(=O)O275C(=C(C=C275)C(=O)O276C(=C(C=C276)C(=O)O277C(=C(C=C277)C(=O)O278C(=C(C=C278)C(=O)O279C(=C(C=C279)C(=O)O280C(=C(C=C280)C(=O)O281C(=C(C=C281)C(=O)O282C(=C(C=C282)C(=O)O283C(=C(C=C283)C(=O)O284C(=C(C=C284)C(=O)O285C(=C(C=C285)C(=O)O286C(=C(C=C286)C(=O)O287C(=C(C=C287)C(=O)O288C(=C(C=C288)C(=O)O289C(=C(C=C289)C(=O)O290C(=C(C=C290)C(=O)O291C(=C(C=C291)C(=O)O292C(=C(C=C292)C(=O)O293C(=C(C=C293)C(=O)O294C(=C(C=C294)C(=O)O295C(=C(C=C295)C(=O)O296C(=C(C=C296)C(=O)O297C(=C(C=C297)C(=O)O298C(=C(C=C298)C(=O)O299C(=C(C=C299)C(=O)O300C(=C(C=C300)C(=O)O301C(=C(C=C301)C(=O)O302C(=C(C=C302)C(=O)O303C(=C(C=C303)C(=O)O304C(=C(C=C304)C(=O)O305C(=C(C=C305)C(=O)O306C(=C(C=C306)C(=O)O307C(=C(C=C307)C(=O)O308C(=C(C=C308)C(=O)O309C(=C(C=C309)C(=O)O310C(=C(C=C310)C(=O)O311C(=C(C=C311)C(=O)O312C(=C(C=C312)C(=O)O313C(=C(C=C313)C(=O)O314C(=C(C=C314)C(=O)O315C(=C(C=C315)C(=O)O316C(=C(C=C316)C(=O)O317C(=C(C=C317)C(=O)O318C(=C(C=C318)C(=O)O319C(=C(C=C319)C(=O)O320C(=C(C=C320)C(=O)O321C(=C(C=C321)C(=O)O322C(=C(C=C322)C(=O)O323C(=C(C=C323)C(=O)O324C(=C(C=C324)C(=O)O325C(=C(C=C325)C(=O)O326C(=C(C=C326)C(=O)O327C(=C(C=C327)C(=O)O328C(=C(C=C328)C(=O)O329C(=C(C=C329)C(=O)O330C(=C(C=C330)C(=O)O331C(=C(C=C331)C(=O)O332C(=C(C=C332)C(=O)O333C(=C(C=C333)C(=O)O334C(=C(C=C334)C(=O)O335C(=C(C=C335)C(=O)O336C(=C(C=C336)C(=O)O337C(=C(C=C337)C(=O)O338C(=C(C=C338)C(=O)O339C(=C(C=C339)C(=O)O340C(=C(C=C340)C(=O)O341C(=C(C=C341)C(=O)O342C(=C(C=C342)C(=O)O343C(=C(C=C343)C(=O)O344C(=C(C=C344)C(=O)O345C(=C(C=C345)C(=O)O346C(=C(C=C346)C(=O)O347C(=C(C=C347)C(=O)O348C(=C(C=C348)C(=O)O349C(=C(C=C349)C(=O)O350C(=C(C=C350)C(=O)O351C(=C(C=C351)C(=O)O352C(=C(C=C352)C(=O)O353C(=C(C=C353)C(=O)O354C(=C(C=C354)C(=O)O355C(=C(C=C355)C(=O)O356C(=C(C=C356)C(=O)O357C(=C(C=C357)C(=O)O358C(=C(C=C358)C(=O)O359C(=C(C=C359)C(=O)O360C(=C(C=C360)C(=O)O361C(=C(C=C361)C(=O)O362C(=C(C=C362)C(=O)O363C(=C(C=C363)C(=O)O364C(=C(C=C364)C(=O)O365C(=C(C=C365)C(=O)O366C(=C(C=C366)C(=O)O367C(=C(C=C367)C(=O)O368C(=C(C=C368)C(=O)O369C(=C(C=C369)C(=O)O370C(=C(C=C370)C(=O)O371C(=C(C=C371)C(=O)O372C(=C(C=C372)C(=O)O373C(=C(C=C373)C(=O)O374C(=C(C=C374)C(=O)O375C(=C(C=C375)C(=O)O376C(=C(C=C376)C(=O)O377C(=C(C=C377)C(=O)O378C(=C(C=C378)C(=O)O379C(=C(C=C379)C(=O)O380C(=C(C=C380)C(=O)O381C(=C(C=C381)C(=O)O382C(=C(C=C382)C(=O)O383C(=C(C=C383)C(=O)O384C(=C(C=C384)C(=O)O385C(=C(C=C385)C(=O)O386C(=C(C=C386)C(=O)O387C(=C(C=C387)C(=O)O388C(=C(C=C388)C(=O)O389C(=C(C=C389)C(=O)O390C(=C(C=C390)C(=O)O391C(=C(C=C391)C(=O)O392C(=C(C=C392)C(=O)O393C(=C(C=C393)C(=O)O394C(=C(C=C394)C(=O)O395C(=C(C=C395)C(=O)O396C(=C(C=C396)C(=O)O397C(=C(C=C397)C(=O)O398C(=C(C=C398)C(=O)O399C(=C(C=C399)C(=O)O400C(=C(C=C400)C(=O)O401C(=C(C=C401)C(=O)O402C(=C(C=C402)C(=O)O403C(=C(C=C403)C(=O)O404C(=C(C=C404)C(=O)O405C(=C(C=C405)C(=O)O406C(=C(C=C406)C(=O)O407C(=C(C=C407)C(=O)O408C(=C(C=C408)C(=O)O409C(=C(C=C409)C(=O)O410C(=C(C=C410)C(=O)O411C(=C(C=C411)C(=O)O412C(=C(C=C412)C(=O)O413C(=C(C=C413)C(=O)O414C(=C(C=C414)C(=O)O415C(=C(C=C415)C(=O)O416C(=C(C=C416)C(=O)O417C(=C(C=C417)C(=O)O418C(=C(C=C418)C(=O)O419C(=C(C=C419)C(=O)O420C(=C(C=C420)C(=O)O421C(=C(C=C421)C(=O)O422C(=C(C=C422)C(=O)O423C(=C(C=C423)C(=O)O424C(=C(C=C424)C(=O)O425C(=C(C=C425)C(=O)O426C(=C(C=C426)C(=O)O427C(=C(C=C427)C(=O)O428C(=C(C=C428)C(=O)O429C(=C(C=C429)C(=O)O430C(=C(C=C430)C(=O)O431C(=C(C=C431)C(=O)O432C(=C(C=C432)C(=O)O433C(=C(C=C433)C(=O)O434C(=C(C=C434)C(=O)O435C(=C(C=C435)C(=O)O436C(=C(C=C436)C(=O)O437C(=C(C=C437)C(=O)O438C(=C(C=C438)C(=O)O439C(=C(C=C439)C(=O)O440C(=C(C=C440)C(=O)O441C(=C(C=C441)C(=O)O442C(=C(C=C442)C(=O)O443C(=C(C=C443)C(=O)O444C(=C(C=C444)C(=O)O445C(=C(C=C445)C(=O)O446C(=C(C=C446)C(=O)O447C(=C(C=C447)C(=O)O448C(=C(C=C448)C(=O)O449C(=C(C=C449)C(=O)O450C(=C(C=C450)C(=O)O451C(=C(C=C451)C(=O)O452C(=C(C=C452)C(=O)O453C(=C(C=C453)C(=O)O454C(=C(C=C454)C(=O)O455C(=C(C=C455)C(=O)O456C(=C(C=C456)C(=O)O457C(=C(C=C457)C(=O)O458C(=C(C=C458)C(=O)O459C(=C(C=C459)C(=O)O460C(=C(C=C460)C(=O)O461C(=C(C=C461)C(=O)O462C(=C(C=C462)C(=O)O463C(=C(C=C463)C(=O)O464C(=C(C=C464)C(=O)O465C(=C(C=C465)C(=O)O466C(=C(C=C466)C(=O)O467C(=C(C=C467)C(=O)O468C(=C(C=C468)C(=O)O469C(=C(C=C469)C(=O)O470C(=C(C=C470)C(=O)O471C(=C(C=C471)C(=O)O472C(=C(C=C472)C(=O)O473C(=C(C=C473)C(=O)O474C(=C(C=C474)C(=O)O475C(=C(C=C475)C(=O)O476C(=C(C=C476)C(=O)O477C(=C(C=C477)C(=O)O478C(=C(C=C478)C(=O)O479C(=C(C=C479)C(=O)O480C(=C(C=C480)C(=O)O481C(=C(C=C481)C(=O)O482C(=C(C=C482)C(=O)O483C(=C(C=C483)C(=O)O484C(=C(C=C484)C(=O)O485C(=C(C=C485)C(=O)O486C(=C(C=C486)C(=O)O487C(=C(C=C487)C(=O)O488C(=C(C=C488)C(=O)O489C(=C(C=C489)C(=O)O490C(=C(C=C490)C(=O)O491C(=C(C=C491)C(=O)O492C(=C(C=C492)C(=O)O493C(=C(C=C493)C(=O)O494C(=C(C=C494)C(=O)O495C(=C(C=C495)C(=O)O496C(=C(C=C496)C(=O)O497C(=C(C=C497)C(=O)O498C(=C(C=C498)C(=O)O499C(=C(C=C499)C(=O)O500C(=C(C=C500)C(=O)O501C(=C(C=C501)C(=O)O502C(=C(C=C502)C(=O)O503C(=C(C=C503)C(=O)O504C(=C(C=C504)C(=O)O505C(=C(C=C505)C(=O)O506C(=C(C=C506)C(=O)O507C(=C(C=C507)C(=O)O508C(=C(C=C508)C(=O)O509C(=C(C=C509)C(=O)O510C(=C(C=C510)C(=O)O511C(=C(C=C511)C(=O)O512C(=C(C=C512)C(=O)O513C(=C(C=C513)C(=O)O514C(=C(C=C514)C(=O)O515C(=C(C=C515)C(=O)O516C(=C(C=C516)C(=O)O517C(=C(C=C517)C(=O)O518C(=C(C=C518)C(=O)O519C(=C(C=C519)C(=O)O520C(=C(C=C520)C(=O)O521C(=C(C=C521)C(=O)O522C(=C(C=C522)C(=O)O523C(=C(C=C523)C(=O)O524C(=C(C=C524)C(=O)O525C(=C(C=C525)C(=O)O526C(=C(C=C526)C(=O)O527C(=C(C=C527)C(=O)O528C(=C(C=C528)C(=O)O529C(=C(C=C529)C(=O)O530C(=C(C=C530)C(=O)O531C(=C(C=C531)C(=O)O532C(=C(C=C532)C(=O)O533C(=C(C=C533)C(=O)O534C(=C(C=C534)C(=O)O535C(=C(C=C535)C(=O)O5

Google Patents

2 of 37

SEARCH TERMS

AB=(oxymorphone NEAR/200 diflunisal) X or
or
TI=(oxymorphone NEAR/200 diflunisal) X or
or
CL=(oxymorphone NEAR/200 diflunisal) X or
or + Synonym

conjugate X or + Synonym

+ Synonym

SEARCH FIELDS

Date · Priority

YYYY-MM-DD — YYYY-MM-DD

Inventor

Assignee

Patent Office · Language

Status · Type

About 37 results

Sort by · Relevance · Grouped by · None · Results / page · 100

Dendrimer conjugates

Application US20100160299A1 · James R. Baker, Jr. · The Regents Of The University Of Michigan
Priority 2008-09-30 · Filing 2009-09-30 · Publication 2010-06-24
The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in ...

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates ...

Application CN106999487A · T.米克尔 · 杭州制药有限公司
Priority 2014-12-02 · Filing 2015-12-02 · Publication 2017-08-01
[0071] Figure 28 provides a rat PK study of intranasal administration profile, by a comparison of the plasma oxymorphone oxymorphone, diflunisal 3 ... 53. The composition according to claim 3, characterized in that, as compared with unconjugated oxymorphone and at least one conjugate provides a ...

Methods and systems of delivering medication via inhalation

Application US20080066741A1 · Edward Lemahieu · Lemahieu Edward
Priority 2006-09-20 · Filing 2007-03-21 · Publication 2008-03-20
Systems and methods for delivery of a drug to the respiratory system of a patient are provided, where the drug is supplied in purified air at a positive pressure relative to atmospheric pressure. With the systems and methods of the present disclosure, medication available in a variety of forms is ...

Methods and systems of delivering medication via inhalation

Application WO2008116165A2 · Edward Lemahieu · Next Safety, Inc.
Priority 2007-03-21 · Filing 2008-03-21 · Publication 2008-09-25
Systems and methods for delivery of a drug to the respiratory system of a patient are provided, where the drug is supplied in purified air at a positive pressure relative to atmospheric pressure. With the systems and methods of the present disclosure, medication available in a variety of forms is ...

Combinations for managing inflammation and associated disorders

Application WO2007072503A2 · Rajesh Jain · Panacea Biotech Ltd.
Priority 2005-12-21 · Filing 2006-12-18 · Publication 2007-06-28
Pharmaceutical compositions comprising at least one analgesic and anti-inflammatory compound(s) that inhibits both cyclooxygenase (COX) and lipoxygenase (LOX) as active agent in combination with at least one another active agent(s) optionally with other pharmaceutically acceptable excipients is ...

The methods and compositions for delivering a biologically active agent

Application JP2008355610A · ロセイヤ エスファンド · インターフェース バイオロジクス インコーポレーテッド
Priority 2005-04-15 · Filing 2006-04-14 · Publication 2008-09-04
The present invention features a biologically active agent and a non-covalently complexed with the polymer. The polymer complex comprises at least one building moiety covalently linked to at least one of the compound sections as combined.

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof

Abstract

The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-Alpha-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxymorphone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxymorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.

Classifications

A61K31/485 Morphinan derivatives, e.g. morphine, codeine
View 8 more classifications

Description

translated from Chinese
Oxymorphone benzoic acid conjugates, the

Claims (56)

translated from Chinese
1. 1. A composition, said composition

Other languages: Chinese

Download PDF
Find Prior Art
Similar

Original Assignee: 杭州制药有限公司
Priority date: 2014-12-02

Family: US (2) EP (1) JP (1) KR (1) CN (1) CA (1) WO (1)

Date: App/Pub Number/Status

2015-12-02CN
201580064812

2017-08-01CN106999487A Application

Info: Patent citations (18), Cited by (1), Legal events, Similar documents, Priority and Related Applications

External links: Espacenet, Global Dossier, Discuss

Google Patents

2 of 37

SEARCH TERMS

TI=(oxymorphone) X or
AB=(oxymorphone) X or
CL=(oxymorphone) X or + Synonym

A61K31 X or A61K47 X or
C07D221 X or C07D489 X or
+ Synonym

conjugat X or + Synonym

+ Synonym G01C11/14

SEARCH FIELDS

Date · Publication

1900-01-01 — 2014-12-02

Inventor

Assignee

Patent Office · Language

Status · Type

About 91 results

Sort by · Relevance · Grouped by · None · Results / page · 100

Composition for nasal administration

Grant US5629011A · Lisbeth Illum · Danbiosyst Uk Limited
Priority 1992-02-05 · Filing 1993-02-04 · Grant 1997-05-13 · Publication 1997-05-13
A composition for nasal administration of polar metabolites of opioid analgesics comprises a polar metabolite of an opioid analgesic and an absorption promoting agent. Preferred metabolites morphine-6-glucuronide and morphine-6-sulphate. A preferred absorption promoting agent is chitosan but other ...

Method of administering narcotic antagonists and analgesics and novel dosage ...

Grant US4464378A · Anwar A. Hussain · University Of Kentucky Research Foundation
Priority 1981-04-28 · Filing 1981-04-28 · Grant 1984-08-07 · Publication 1984-08-07
The invention provides a novel method of administering narcotic antagonists, narcotic analgesics and related compounds, and novel dosage forms containing these compounds which are adapted for nasal administration. The nasal dosage forms disclosed include solutions, suspensions, gels and ointments.

Polymer conjugates of opioid antagonists

Grant US7056500B2 · Michael David Bentley · Nektar Therapeutics AI, Corporation
Priority 2001-10-18 · Filing 2002-10-18 · Grant 2006-06-06 · Publication 2006-06-06
..., fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine (pethidine), methadone, morphine, nalbuphine, noscapine, oxycodone, oxymorphone, ... or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of ...

Sustained release formulations of oxymorphone

Grant US7276250B2 · Anand R. Baichwal · Penwest Pharmaceuticals Company
Priority 2001-07-06 · Filing 2002-07-03 · Grant 2007-10-02 · Publication 2007-10-02
... administration, and as 5 mg rectal suppositories. At one time, a 10 mg oral immediate release tablet formation of oxymorphone HCl was marketed. Oxymorphone HCl is metabolized principally in the liver and undergoes conjugation with glucuronic acid and reduction to 6 alpha and beta hydroxy epimers.

Oral dosage forms with therapeutically active agents in controlled release ...

Application US20040224020A1 · Grant Schoenhard · Schoenhard Grant L.
Priority 2002-12-18 · Filing 2003-12-18 · Publication 2004-11-11
The present invention relates to oral dosage form with active agents in controlled release cores and in immediate release gelatin capsule coats.

Top 1000 results by filing date

Relative count of top 5 values

Assignees	Inventors	CPCs
Nektar Therapeutics A61K47/60 A61K47/56 A61K47/59 A61K31/485		4.4%
Regents Of The University Of Minnesota A61K47/55 A61K47/50 A61K47/51 A61K47/54		4.4%
Endo Pharmaceuticals, Inc. A61K47/38 A61K47/02 A61K47/26 A61K47/36		3.3%
Shire Ltd C07D223/04 C07D223/02 C07D223/00 C07D223		3.3%
Penwest Pharmaceuticals Co. A61K9/2009 A61K9/2018 A61K9/205 A61K9/203		2.2%

Expand